# FDA 483 - Sant P. Chawla, MD - June 30, 2026

Source: https://www.keypedia.com/records/483/sant-p-chawla-md/1152fde2-17e7-4262-aaad-e80f433e6fcc

> FDA 483 for Sant P. Chawla, MD on June 30, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Sant P. Chawla, MD
- Inspection Date: 2026-06-30
- Product Type: drugs
- Office Name: Los Angeles District Office
- Summary: An FDA inspection of Sant P. Chawla, M.D., Clinical Investigator, in Santa Monica, revealed significant deficiencies in the conduct of a clinical study. The firm failed to adhere to the study protocol's eligibility criteria for multiple subjects and did not maintain adequate and accurate case histories, with discrepancies found between source documents and the electronic data capturing system.

## Related Documents

- [483 - 2022-04-15](https://www.keypedia.com/records/483/sant-p-chawla-md/0a32a8a1-6d5e-481b-917d-19be4066a625) — date: April 15, 2022

## Related Officers

- [Jose A. Leyva](https://www.keypedia.com/people/jose-a-leyva/0c0ffdd3-cd41-4e30-bf61-e96f62a58921)
- [Bruno Baltazar](https://www.keypedia.com/people/bruno-baltazar/95a94f09-6e24-4454-a18d-4cef89e721d9)

Company: https://www.keypedia.com/companies/sant-p-chawla-md/12b13bee-4e0f-4d72-a3a7-217e48fb68ef

Office: https://www.keypedia.com/offices/los-angeles-district-office/edcf1dfe-596a-43b8-8df4-07d9cd94763b